Bristol-Myers Squibb Company
NYSE
Bristol-Myers Squibb Company's latest marketcap:
As of 06/09/2025, Bristol-Myers Squibb Company's market capitalization has reached $99.93 B. According to our data, Bristol-Myers Squibb Company is the 189th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 99.93 B |
| Revenue (ttm) | 47.64 B |
| Net Income (ttm) | 5.42 B |
| Shares Out | 2.04 B |
| EPS (ttm) | 2.67 |
| Forward PE | 7.52 |
| Ex-Dividend Date | 04/04/2025 |
| Earnings Date | 07/25/2025 |
Bristol-Myers Squibb Company's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/09/2025 | $99.93 B | -14.12% |
| 12/31/2024 | $114.71 B | 9.88% |
| 12/29/2023 | $104.4 B | -31.75% |
| 12/30/2022 | $152.98 B | 10.54% |
| 12/31/2021 | $138.39 B | -1.27% |
| 12/31/2020 | $140.17 B | 34.03% |
| 12/31/2019 | $104.58 B | 23.27% |
| 12/31/2018 | $84.84 B | -15.41% |
| 12/29/2017 | $100.3 B | 2.69% |
| 12/30/2016 | $97.67 B | -14.9% |
Company Profile
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is a global biopharmaceutical firm engaged in the discovery, development, licensing, manufacturing, and distribution of innovative medicines. The company serves patients worldwide with a focus on oncology, hematology, immunology, cardiovascular, neuroscience, and other therapeutic areas.
Key Products
- Eliquis – Reduces stroke risk in non-valvular atrial fibrillation and treats DVT/PE.
- Opdivo – Used for various anti-cancer indications.
- Pomalyst/Imnovid – Treats multiple myeloma.
- Orencia – Addresses active rheumatoid arthritis and psoriatic arthritis.
- Sprycel – For Philadelphia chromosome-positive chronic myeloid leukemia.
- Yervoy – Treats unresectable or metastatic melanoma.
- Empliciti – Targets relapsed/refractory multiple myeloma.
- Abecma – For relapsed or refractory multiple myeloma.
- Reblozyl – Treats anemia.
- Opdualag – Addresses unresectable or metastatic melanoma.
- Zeposia – Treats relapsing forms of multiple sclerosis.
- Breyanzi – For relapsed or refractory large B-cell lymphoma.
- Revlimid – An oral immunomodulatory drug for multiple myeloma.
- Abraxane – Treats breast cancer, NSCLC, and pancreatic cancer.
Additional Offerings
The company also provides treatments such as Cobenfy (schizophrenia), Krazati (KRASG12C-mutated NSCLC), Camzyos (symptomatic obstructive HCM), Sotyktu (plaque psoriasis), and Augtyro (ROS1-positive NSCLC).
Distribution & History
Bristol-Myers Squibb distributes its products to wholesalers, pharmacies, hospitals, clinics, and government agencies. Founded in 1887 as Bristol-Myers Company, the firm is headquartered in Princeton, New Jersey.
Frequently Asked Questions
-
What is Bristol-Myers Squibb Company's (BMY) current market cap?As of 06/09/2025, Bristol-Myers Squibb Company (including the parent company, if applicable) has an estimated market capitalization of $99.93 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Bristol-Myers Squibb Company (BMY) rank globally by market cap?Bristol-Myers Squibb Company global market capitalization ranking is approximately 189 as of 06/09/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.